NEW ZEALAND DATA SHEET

1 HEXAXIM (SUSPENSION FOR INJECTION)

Hexaxim 0.5 mL, suspension for injection

Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and *Haemophilus influenzae* type b conjugate vaccine (adsorbed).

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Hexaxim is a preservative free liquid formulation for intramuscular administration which combines: Diphtheria and Tetanus toxoids, Acellular Pertussis (2-component), Recombinant Hepatitis B surface antigen, Inactivated Poliomyelitis virus and *Haemophilus influenzae* type b polysaccharide conjugated to tetanus protein

Each 0.5 mL, adsorbed to aluminium hydroxide hydrate (0.6 mg Al$^{3+}$), contains:

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Quantity (per 0.5 mL dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria Toxoid</td>
<td>≥ 20 IU$^1$</td>
</tr>
<tr>
<td>Tetanus Toxoid</td>
<td>≥ 40 IU$^2$</td>
</tr>
<tr>
<td>Bordetella Pertussis</td>
<td></td>
</tr>
<tr>
<td>Pertussis Toxoid</td>
<td>25 microgram</td>
</tr>
<tr>
<td><em>Pertussis Filamentous Haemagglutinin</em></td>
<td>25 microgram</td>
</tr>
<tr>
<td><em>Hepatitis B</em> surface antigen$^3$</td>
<td>10 microgram</td>
</tr>
<tr>
<td><em>Poliovirus (Inactivated)</em>$^4$</td>
<td></td>
</tr>
<tr>
<td>Type 1 (Mahoney)</td>
<td>40 D antigen$^5$ Units$^6$</td>
</tr>
<tr>
<td>Type 2 (MEF-1)</td>
<td>8 D antigen$^5$ Units$^6$</td>
</tr>
<tr>
<td>Type 3 (Saukett)</td>
<td>32 D antigen$^5$ Units$^6$</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> type B polysaccharide conjugated to Tetanus protein*</td>
<td>12 microgram</td>
</tr>
<tr>
<td></td>
<td>22 – 36 microgram</td>
</tr>
</tbody>
</table>

1 As lower confidence limit (p= 0.95) and not less than 30 I.U as mean value
2 As lower confidence limit (p= 0.95)
3 Or equivalent activity determined by an immunogenicity evaluation
4 Surface antigen of hepatitis B virus produced from recombinant strain of the yeast Hansenula polymorpha
5 Produced on vero cells
6 Quantity of antigen in the final bulk product, according to WHO (TRS 673, 1992)
7 Or equivalent antigenic quantity determined by a suitable immunochemical method
The vaccine may contain traces of glutaral, formaldehyde, neomycin, streptomycin and polymyxin B.

Contains phenylalanine. For the full list of excipients, see section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

4 HEXAXIM IS A WHITISH CLOUDY SUSPENSION FOR INJECTION. CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

Use of this vaccine should be in accordance with the national recommendation as per the current Immunisation Handbook.

4.2 DOSE AND METHOD OF ADMINISTRATION

Hexaxim is for intramuscular injection according to the dosing schedule below.

<table>
<thead>
<tr>
<th>Dose</th>
<th>Vaccination</th>
<th>Dosing Schedule</th>
<th>General Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Dose</td>
<td>Primary*</td>
<td>Three doses of 0.5 mL (such as: 6, 10, 14 weeks; 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months)</td>
<td>There should be an interval of at least 4 weeks between primary doses in accordance with the national recommendation as per the current Immunisation Handbook.</td>
</tr>
<tr>
<td></td>
<td>Booster</td>
<td>A booster dose may be given</td>
<td>The booster dose should be given at least 6 months after the last priming dose and in accordance with the national recommendation as per the current Immunisation Handbook.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>In case where a booster dose is not administrated, a dose of Hib vaccine should be given.</td>
</tr>
</tbody>
</table>
### Dose Vaccination Dosing Schedule General Considerations

<table>
<thead>
<tr>
<th>Dose</th>
<th>Vaccination</th>
<th>Dosing Schedule</th>
<th>General Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Dose</td>
<td>Primary*</td>
<td>Two doses of 0.5 mL (such as 2, 4 months; 3, 5 months)</td>
<td>There should be an interval of at least 8 weeks between primary doses and in accordance with the national recommendation as per the current Immunisation Handbook.</td>
</tr>
<tr>
<td></td>
<td>Booster</td>
<td>A booster dose must be given</td>
<td>The booster dose should be given at least 6 months after the last priming dose in accordance with the national recommendation as per the current Immunisation Handbook. In case where a booster dose is not administrated, a dose of Hib vaccine must be given.</td>
</tr>
</tbody>
</table>

*Where a dose of hepatitis B vaccine is given at birth, Hexaxim can be used for supplementary doses of hepatitis B vaccine from the age of 6 weeks. If a second dose of hepatitis B vaccine is required before this age, monovalent hepatitis B vaccine should be used.

For further information, refer to the current Immunisation Handbook.

**Administration**

Before use, the vaccine should be shaken in order to obtain a homogeneous whitish cloudy suspension.

Hexaxim should be administered intramuscularly. The recommended injection sites are generally the antero-lateral aspect of the upper thigh in infants and toddlers and the deltoid muscle in older children.

Do not administer via intravascular route: ensure that the needle does not penetrate a blood vessel.

Do not administer by intradermal or subcutaneous injection.

Separate syringes, separate injection sites and preferably separate limbs must be used in case of concomitant administration with other vaccines.

Hexaxim is for single use only and must not be used in more than one individual. Discard any remaining unused contents.

#### 4.3 CONTRAINDICATIONS

Hexaxim should not be administered to anyone with a history of severe allergic reaction to any component of the vaccine or to any pertussis vaccine, after previous administration of the vaccine or a vaccine containing the same components or constituents.
Vaccination with Hexaxim is contraindicated if the individual has experienced an encephalopathy of unknown aetiology within 7 days of administration of a previous dose of any vaccine containing pertussis antigens (whole cell or acellular pertussis vaccines). In these circumstances pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria, tetanus, hepatitis B, poliomyelitis and Hib vaccines.

Progressive neurological disorder, uncontrolled epilepsy, progressive encephalopathy. Pertussis vaccine should not be administered to individuals with these common conditions until the treatment regimen has been established, the condition has stabilised and the benefit clearly outweighs the risk.

Generally vaccination must be postponed in cases of moderate or severe febrile and/or acute disease and low-grade fever does not constitute a contraindication.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Do not administer intravenously, intradermally or subcutaneously.

Prior to vaccination

Anaphylaxis

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following administration of the vaccine.

Hypersensitivity

As each dose may contain undetectable traces of glutaraldehyde, formaldehyde, neomycin, streptomycin and polymyxin B, caution should be exercised when the vaccine is administered to individuals with hypersensitivity to these substances.

Bleeding disorder

As with all injectable vaccines, the vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.

Previous pertussis vaccination

If any of the following events are known to have occurred in temporal relation to receipt of pertussis-containing vaccine, the decision to give further doses of pertussis-containing vaccine should be carefully considered:

- Temperature of ≥ 40°C within 48 hours not due to another identifiable cause.
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
- Persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination.
- Convulsions with or without fever, occurring within 3 days of vaccination.

**Family and individual history**

A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome (SIDS) do not constitute a contraindication for the use of Hexaxim. Individuals with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.

**Syncope**

Syncope can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent falling and injury and to manage syncope.

**Protection**

Hexaxim will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or *Haemophilus influenzae* type b. However, it can be expected that hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.

Hexaxim will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or by other liver pathogens.

Because of the long incubation period of hepatitis B, it is possible for unrecognised hepatitis B infection to be present at the time of vaccination. The vaccine may not prevent hepatitis B infection in such cases.

Hexaxim does not protect against infectious diseases caused by other types of *Haemophilus influenzae* or against meningitis of other origins.

As with any vaccine, vaccination with Hexaxim may not protect 100% of susceptible individuals.

**Special patient groups**

**Premature and low birth weight infants**

Immunogenicity data are available for 105 preterm infants. These data support the use of Hexaxim in preterm infants. As expected in preterm infants, lower immune response has been observed for some antigens, when indirectly compared to term infants, although seroprotective levels have been achieved (see Section 5.1 Pharmacodynamic properties - Clinical trials). No safety data were collected in preterm infants (born ≤ 37 weeks of gestation) in clinical trials.

The potential risk of apnoea and the need for respiratory monitoring for 48-72 hours should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory
immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

**Immunocompromised individuals**

The immunogenicity of the vaccine may be reduced by immunosuppressive treatment or immunodeficiency. It is recommended to postpone vaccination until the end of such treatment or disease. Nevertheless, vaccination of individuals with chronic immunodeficiency such as HIV infection is recommended even if the antibody response may be limited.

Immunogenicity data in HIV-exposed infants (infected and uninfected) showed that Hexaxim is immunogenic in the potentially immunodeficient population of HIV-exposed infants whatever their HIV status at birth (See Section 5.1 Pharmacodynamic properties - Clinical trials). No specific safety concern was observed in this population.

**Neurological disorder**

If Guillain Barré syndrome or brachial neuritis has occurred following receipt of prior vaccine containing tetanus toxoid, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks, such as whether or not the primary immunisation schedule has been completed. Vaccination is usually justified for infants whose primary immunisation schedules are incomplete (i.e. fewer than three doses have been received).

Some case reports of multiple sclerosis have been reported after administration of hepatitis B vaccine. To date a causal relationship has not been demonstrated with hepatitis B vaccine.

**Chronic renal failure**

In individuals with chronic renal failure, an impaired hepatitis B response is observed and administration of additional doses of hepatitis B vaccine should be considered according to the antibody level against hepatitis B virus surface antigen (anti-HBsAg).

**Genetic polymorphism**

Immune responses to the vaccine have not been studied in the context of genetic polymorphism.

**Paediatric Population**

The safety and efficacy of Hexaxim in children over 24 months of age have not been established.

**Use in the elderly**

Not applicable.
Genotoxicity
Hexaxim has not been evaluated for genotoxic potential.

Carcinogenicity
Hexaxim has not been evaluated for carcinogenic potential.

Effect on Laboratory Tests
Interference of Hexaxim with laboratory and/or diagnostic tests has not been studied.

However, Antigenuria (PRP antigen) has been detected in some instances following receipt of Haemophilus influenzae type b conjugate vaccine. Therefore, urine antigen detection may not have definite diagnostic value in suspected Haemophilus influenzae type b disease within two weeks of immunisation.

4.5 INTERACTION WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTION
Hexaxim must not be mixed with other vaccines or other parenterally administered drugs.

Separate injection sites must be used in case of concomitant administration.

Data on concomitant administration of Hexaxim with 7-valent or 13-valent pneumococcal polysaccharide conjugate vaccines have shown no clinically relevant interference in the antibody response to each of the individual antigens.

Data on concomitant administration of Hexaxim with measles-mumps-rubella vaccine and with varicella vaccine have shown no clinically relevant interference in the antibody response to each of the antigens when given as a booster vaccination.

Data on concomitant administration of rotavirus vaccines have shown no clinically relevant interference in the antibody response to each of the antigens.

Data on concomitant administration of Hexaxim with a meningococcal serogroup C-tetanus toxoid conjugate vaccine or a meningococcal serogroups A, C, W-135, Y-tetanus toxoid conjugate vaccine have shown no clinically relevant interference in the antibody response to each of the antigens.

Except in the case of immunosuppressive therapy (see section 4.4 Special warnings and precautions for use), no significant clinical interaction with other treatments or biological products has been reported.
4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility

Animal studies have not been conducted to determine the effects of Hexaxim on fertility.

Use in Pregnancy (Category B2)

Hexaxim is not indicated for use during pregnancy and has not been evaluated for potential harmful effects during pregnancy in animals or humans.

Use in Lactation

Hexaxim is not indicated for use in lactating women and it is not known whether Hexaxim components are excreted in human milk.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Not applicable

4.8 UNDESIRABLE EFFECTS

The adverse events are ranked under headings of frequency per dose, using the following convention:

- **Very common** \( \geq 1/10 \) (\( \geq 10\% \))
- **Common** \( \geq 1/100 \) to \( < 1/10 \) (\( \geq 1\% \) and \( < 10\% \))
- **Uncommon** \( \geq 1/1,000 \) to \( < 1/100 \) (\( \geq 0.1\% \) and \( < 1\% \))
- **Rare** \( \geq 1/10,000 \) to \( < 1/1000 \) (\( \geq 0.01\% \) and \( < 0.1\% \))
- **Very rare** \( < 1/10,000 \) (\( < 0.01\% \))
- **Not known** Cannot be estimated from available data

Clinical Trials Experience

In clinical studies in individuals who received Hexaxim, the most frequently reported reactions (expressed per dose) include injection site pain, irritability, crying and injection site erythema. Slightly higher solicited reactogenicity was observed after the first dose compared to subsequent doses.

Immune system disorders

Uncommon: Hypersensitivity reaction
Metabolism and nutrition disorders

Very common: Anorexia

Nervous system disorders

Very common: Crying, somnolence

Common: Abnormal crying (prolonged crying)

Very rare: Hypotonic reactions or hypotonic-hyporesponsive episodes (HHE)

Gastrointestinal disorders

Very common: Vomiting

Common: Diarrhoea

Skin and subcutaneous tissue disorders

Rare: Rash

General disorders and administration site conditions

Very common: Injection site pain, injection site erythema, injection site swelling, irritability, pyrexia (body temperature ≥ 38.0°C)

Common: Injection site induration

Uncommon: Injection site nodule, pyrexia (body temperature ≥ 39.6°C)

Rare: Extensive limb swelling

Large injection site reactions (> 50 mm), including extensive limb swelling from the injection site beyond one or both joints, have been reported in children. These reactions start within 24-72 hours after vaccination, may be associated with erythema, warmth, tenderness or pain at the injection site and resolve spontaneously within 3-5 days. The risk appears to be dependent on the number of prior doses of acellular pertussis containing vaccine, with a greater risk following the 4th and 5th doses.

Adverse Reactions from Post-Marketing Surveillance

Immune system disorders

Very rare: Anaphylactic reactions

Nervous system disorders

Very rare: Convulsions with or without fever
Potential adverse events

(i.e. adverse events which have been reported with other vaccines containing one or more of the components or constituents of Hexaxim and not directly with Hexaxim).

- Brachial neuritis and Guillain Barré Syndrome have been reported after administration of a tetanus toxoid containing vaccine.

- Oedematous reaction affecting one or both lower limbs may occur following vaccination with Haemophilus Influenzae type b containing vaccines. If this reaction occurs, it is mainly after primary injections and within the first few hours following vaccination. Associated symptoms may include cyanosis, redness, transient purpura and severe crying. All events resolve spontaneously without sequel within 24 hours.

- Peripheral neuropathy (polyradiculoneuritis, facial paralysis), optic neuritis, central nervous system demyelination (multiple sclerosis) have been reported after administration of an hepatitis B antigen containing vaccine.

- Encephalopathy/encephalitis

- Apnoea in very premature infants (≤ 28 weeks of gestation) (see section 4.4 Special warnings and precautions for use)

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at https://nzphvc.otago.ac.nz/reporting/.

4.9 OVERDOSE

Not documented.

For general advice on overdose management, contact the National Poisons Centre, 0800 POISON or 0800 764 766.

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Vaccines, Bacterial and viral vaccines combined, ATC code: J07CA09

Mechanism of action

Hexaxim induces the production of antibodies against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
Clinical trials

The primary vaccination schedules that have been used are: 3, 5 months without hepatitis B vaccination at birth; 6, 10, 14 weeks with and without hepatitis B vaccination at birth; 2, 3, 4 months without hepatitis B vaccination at birth; 2, 4, 6 months with and without hepatitis B vaccination at birth.

Results obtained in the clinical studies for each of the components are summarised in the tables below:

**Table 3 - Percentage of individuals with antibody titres $\geq$ seroprotection/seroconversion rates$^a$ one month after primary vaccination with 2 or 3 doses of Hexaxim**

<table>
<thead>
<tr>
<th>Antibody titres $\geq$ seroprotection/seroconversion rates</th>
<th>2 Doses</th>
<th>3 Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3-5 months N=249$^b$</td>
<td>6-10-14 Weeks N=123 to 220$^c$</td>
</tr>
<tr>
<td>Anti-diphtheria ($\geq$ 0.01 IU/ml)</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Anti-tetanus ($\geq$ 0.01 IU/ml)</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-PT ($\geq$ 4 fold rise)</td>
<td>93.4</td>
<td>93.6</td>
</tr>
<tr>
<td>Anti-FHA ($\geq$ 4 fold rise)</td>
<td>92.5</td>
<td>93.1</td>
</tr>
<tr>
<td>Anti-HBs ($\geq$ 10 mIU/ml) with hepatitis B vaccination at birth</td>
<td>/</td>
<td>99.0</td>
</tr>
<tr>
<td>Anti-HBs ($\geq$ 10 mIU/ml) without hepatitis B vaccination at birth</td>
<td>97.2</td>
<td>95.7</td>
</tr>
<tr>
<td>Anti-Polio type 1 ($\geq$ 8 (1/dilution))</td>
<td>90.8</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-Polio type 2 ($\geq$ 8 (1/dilution))</td>
<td>95.0</td>
<td>98.5</td>
</tr>
<tr>
<td>Anti-Polio type 3 ($\geq$ 8 (1/dilution))</td>
<td>96.7</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-PRP ($\geq$ 0.15 µg/ml)</td>
<td>71.5</td>
<td>95.4</td>
</tr>
</tbody>
</table>

$^a$: Generally accepted surrogates (PT, FHA) or correlates of protection (other components)

$^b$: 3, 5 months without hepatitis B vaccination at birth (Finland, Sweden)

$^c$: 6, 10, 14 weeks with and without hepatitis B vaccination at birth (Republic of South Africa)

$^d$: 2, 3, 4 months without hepatitis B vaccination at birth (Finland)

$^e$: 2, 4, 6 months without hepatitis B vaccination at birth (Argentina, Mexico, Peru) and with hepatitis vaccination at birth (Costa Rica and Colombia)
Table 4 - Percentage of individuals with antibody titres ≥ seroprotection/seroconversion rates one month after booster vaccination with Hexaxim

<table>
<thead>
<tr>
<th>Antibody titres ≥ seroprotection/seroconversion rates</th>
<th>Booster vaccination at 11-12 months of age after a two dose primary course</th>
<th>Booster vaccination during the second year of life following a three dose primary course</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3-5 months N=249ᵇ</td>
<td>6-10-14 weeks N=204ᶜ</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Anti-diphtheria (≥ 0.1 IU/ml)</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-tetanus (≥ 0.1 IU/ml)</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-PT (≥ 4 fold rise)</td>
<td>94.3</td>
<td>94.4</td>
</tr>
<tr>
<td>Anti-FHA (≥ 4 fold rise)</td>
<td>97.6</td>
<td>99.4</td>
</tr>
<tr>
<td>Anti-HBs (≥ 10 mIU/ml)</td>
<td>With hepatitis B vaccination at birth</td>
<td>/</td>
</tr>
<tr>
<td></td>
<td>Without hepatitis B vaccination at birth</td>
<td>96.4</td>
</tr>
<tr>
<td>Anti-Polio type 1 (≥ 8 (1/dilution))</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-Polio type 2 (≥ 8 (1/dilution))</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-Polio type 3 (≥ 8 (1/dilution))</td>
<td>99.6</td>
<td>100.0</td>
</tr>
<tr>
<td>Anti-PRP (≥ 1.0 µg/ml)</td>
<td>93.5</td>
<td>98.5</td>
</tr>
</tbody>
</table>

N = Number of individuals analysed (per protocol set)

a: Generally accepted surrogates (PT, FHA) or correlates of protection (other components)
b: 3, 5 months without hepatitis B vaccination at birth (Finland, Sweden)
c: 6, 10.14 weeks with and without hepatitis B vaccination at birth (Republic of South Africa)
d: 2, 3, 4 months without hepatitis B vaccination at birth (Finland)
e: 2, 4, 6 months without hepatitis B vaccination at birth (Mexico)

Immune responses to Hexaxim in preterm infants

Immune responses to Hexaxim antigens in preterm (105) infants (born after a gestation period of 28 to 36 weeks), including 90 infants born to women vaccinated with Tdap vaccine during pregnancy and 15 to women not vaccinated during pregnancy, were evaluated following a 3-dose primary vaccination course at 2, 3 and 4 months of age and a booster dose at 13 months of age.

One month after primary vaccination, all subjects were seroprotected against diphtheria (≥ 0.01 IU/mL), tetanus (≥ 0.01 IU/mL) and poliovirus types 1, 2 and 3 (≥ 8 (1/dilution)); 89.8% of subjects were seroprotected against hepatitis B (≥ 10 IU/mL) and 79.4% were seroprotected against Hib invasive diseases (≥ 0.15 µg/mL).
One month after the booster dose, all subjects were seroprotected against diphtheria (≥ 0.1 IU/mL), tetanus (≥ 0.1 IU/mL) and poliovirus types 1, 2 and 3 (≥ 8 (1/dilution)); 94.6% of subjects were seroprotected against hepatitis B (≥ 10 IU/mL) and 90.6% were seroprotected against Hib invasive diseases (≥ 1 µg/mL).

Regarding pertussis, one month after primary vaccination 98.7% and 100% of subjects developed antibodies ≥ 8 EU/mL against PT and FHA antigens respectively. One month after the booster dose 98.8% of subjects developed antibodies ≥ 8 EU/mL against both PT and FHA antigens. Pertussis antibody concentrations were increased by 13-fold after primary vaccination and by 6- to 14-fold after the booster dose.

**Immune responses to Hexaxim in infants born to women vaccinated with Tdap during pregnancy**

Immune responses to Hexaxim antigens in term (109) and preterm (90) infants born to women vaccinated with Tdap vaccine during pregnancy (between 24 and 36 weeks of gestation) were evaluated following a 3-dose primary vaccination course at 2, 3 and 4 months of age and a booster dose at 13 (preterm infants) or 15 (term infants) months of age.

One month after primary vaccination, all subjects were seroprotected against diphtheria (≥ 0.01 IU/mL), tetanus (≥ 0.01 IU/mL) and poliovirus types 1 and 3 (≥ 8 (1/dilution)); 97.3% of subjects were seroprotected against poliovirus type 2 (≥ 8 (1/dilution)); 94.6% of subjects were seroprotected against hepatitis B (≥ 10 IU/mL) and 88.0% were seroprotected against Hib invasive diseases (≥ 0.15 µg/mL).

One month after the booster dose, all subjects were seroprotected against diphtheria (≥ 0.1 IU/mL), tetanus (≥ 0.1 IU/mL) and poliovirus types 1, 2 and 3 (≥ 8 (1/dilution)); 93.9% of subjects were seroprotected against hepatitis B (≥ 10 IU/mL) and 94.0% were seroprotected against Hib invasive diseases (≥ 1 µg/mL).

Regarding pertussis, one month after primary vaccination 99.4% and 100% of subjects developed antibodies ≥ 8 EU/mL against PT and FHA antigens respectively. One month after the booster dose 99.4% of subjects developed antibodies ≥ 8 EU/mL against both PT and FHA antigens. Pertussis antibody concentrations were increased by 5- to 9-fold after primary vaccination and by 8- to 19-fold after the booster dose.

**Immune responses to Hexaxim in HIV-exposed infants**

Immune responses to Hexaxim antigens in 51 HIV-exposed infants (9 infected and 42 uninfected) were evaluated following a 3-dose primary vaccination course at 6, 10 and 14 weeks of age and a booster dose at 15 to 18 months of age.

One month after primary vaccination, all infants were seroprotected against diphtheria (≥ 0.01 IU/mL), tetanus (≥ 0.01 IU/mL) and poliovirus types 1, 2 and 3 (≥ 8 (1/dilution)), hepatitis B (≥ 10 IU/mL), and more than 97.6% for Hib invasive diseases (≥ 0.15 µg/mL).

One month after the booster dose, all subjects were seroprotected against diphtheria (≥ 0.1 IU/mL), tetanus (≥ 0.1 IU/mL), poliovirus types 1, 2 and 3 (≥ 8 (1/dilution), hepatitis B (≥ 10 IU/mL), and more than 96.6% for Hib invasive diseases (≥ 1 µg/mL).

hexa-ccdsv8-ccdsv10-dsv7-15feb23
Regarding pertussis, one month after primary vaccination, 100% of subjects developed antibodies ≥ 8 EU/mL against both PT and FHA antigens. One month after the booster dose, 100% of subjects developed antibodies ≥ 8 EU/mL against both PT and FHA antigens. Seroconversion rates defined as minimum 4-fold increase compared to pre-vaccination level (pre-dose 1) were 100% in the HIV-exposed and infected group for anti-PT and anti-FHA, and 96.6% for anti-PT and 89.7% for anti-FHA in the HIV-exposed and uninfected group.

**Efficacy and effectiveness in protecting against pertussis**

The long term capability of the acellular pertussis antigens contained in Hexaxim to reduce pertussis incidence and control pertussis disease has been demonstrated in a 15-year national pertussis surveillance on pertussis disease in Sweden with the pentavalent DTPa-IPV/Hib vaccine using a 3, 5, 12 months schedule. Several types of acellular pertussis vaccines were used during the 15 year follow-up. It is not possible to detect differences in vaccine effectiveness using surveillance data due to different vaccines and schedules used during the study period, variability in vaccine coverage and surveillance systems and cyclic variations in infection and disease.

**Effectiveness in protecting against Hib invasive disease**

The vaccine effectiveness against Hib invasive disease of DTPa and Hib combination vaccines (pentavalent and hexavalent including vaccines containing the Hib antigen from Hexaxim) has been demonstrated in Germany via an extensive (over five years follow-up period) post-marketing surveillance study. The vaccine effectiveness was of 96.7% for the full primary series, and 98.5% for booster dose (irrespective of priming).

5.2 PHARMACOKINETIC PROPERTIES

No pharmacokinetic studies have been performed.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Hexaxim has not been evaluated for genotoxic potential.

Carcinogenicity

Hexaxim has not been evaluated for carcinogenic potential.
6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Hexaxim contains the excipients; dibasic sodium phosphate, monobasic potassium phosphate, trometamol, sucrose, essential amino acids (cystine, tyrosine, arginine hydrochloride, histidine, isoleucine, leucine, lysine hydrochloride, methionine, phenylalanine, threonine, tryptophan and valine) and water for injections.

The manufacture of this product includes exposure to bovine materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

6.2 INCOMPATIBILITIES

In the absence of compatibility studies, this vaccine must not be mixed with other vaccines or medicinal products.

6.3 SHELF LIFE

48 months

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store in a refrigerator (2°C – 8°C). Do not freeze. Discard if vaccine has been frozen.

Protect from light.

Stability data indicate that the vaccine components are stable at temperatures up to 25°C for 72 hours. At the end of this period, Hexaxim should be used or discarded. These data are intended to guide healthcare professionals in case of temporary temperature excursion only.

6.5 NATURE AND CONTENTS OF CONTAINER

Hexaxim is supplied in:

- 0.5 mL single dose in pre-filled syringe without attached needle and one separate needle in a pack.
- 0.5 mL single dose in pre-filled syringe without attached needle and two separate needles in a pack.

Pack size of 1 or 10. Not all pack sizes may be marketed.
6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

After use, any remaining vaccine and container must be disposed of safely according to locally agreed procedures.

7 MEDICINE SCHEDULE

Prescription Only Medicine

8 SPONSOR

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics
PO Box 62027
Sylvia Park Auckland 1644
Freecall: 0800 283 684
Email: medinfo.australia@sanofi.com

9 DATE OF FIRST APPROVAL

6 March 2014

10 DATE OF REVISION OF THE TEXT

15 February 2023

Table 5 - Summary of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Tetanus toxoid footnote update in line with test method</td>
</tr>
<tr>
<td>4.4</td>
<td>Added warning of Syncope and additional information for use in pre-term infants and HIV-exposed infants</td>
</tr>
<tr>
<td>5.1</td>
<td>Additional clinical data on immune response in pre-term infants, infants born to women vaccinated during pregnancy and HIV-exposed infants</td>
</tr>
</tbody>
</table>